|
Patent landscape, scope, and claims: |
Analysis of Patent US 8,987,333: Scope, Claims, and Patent Landscape
What is the scope of patent US 8,987,333?
Patent US 8,987,333 is a U.S. patent granted on March 24, 2015, assigned to Johnson & Johnson Innovation. The patent covers a novel chemical compound and its pharmaceutical uses, specifically targeting treatment of neurodegenerative diseases such as Alzheimer's disease. The scope encompasses both the chemical composition and its application as a therapeutic agent.
The patent claims a class of compounds with a core structure defined by a specific chemical scaffold, modified by certain substituents, which exhibit activity as cholinesterase inhibitors. The scope extends to pharmaceutical compositions containing the compound, methods of use in treating cholinergic deficits, and methods of synthesis.
The primary focus is on a specific chemical formula, with detailed substitutions outlined in the claims. The claims explicitly include:
- The chemical structure with variations at particular positions.
- Methods of synthesizing the compounds.
- Therapeutic methods related to neurodegenerative diseases.
The scope is intentionally broad to encompass a wide range of structurally related compounds and their uses, providing patent protection for the core chemical series and related analogs.
What are the primary claims of the patent?
The patent includes 15 claims, with Claims 1 through 3 being independent:
-
Claim 1: Defines a chemical compound with a specific core structure, where R1 and R2 are substituents selected from a set of designated groups. It covers compounds where R1 and R2 can independently be hydrogen, methyl, or other specified groups.
-
Claim 2: Asserts a pharmaceutical composition comprising the compound of Claim 1, combined with a pharmaceutically acceptable carrier.
-
Claim 3: Describes a method for treating Alzheimer’s disease by administering an effective amount of the compound of Claim 1.
Dependent claims specify particular substitutions, stereochemistry, or formulations, providing detailed scope.
Key points from claims:
- Focus on a specific chemical scaffold with variable substituents.
- Inclusion of both the chemical compounds and pharmaceutical compositions.
- Therapeutic methods of administering the compounds for neurodegenerative diseases.
The specific language limits the scope to compounds falling within the defined chemical space and their use in treatment.
What is the patent landscape surrounding US 8,987,333?
The landscape includes patents filed by Johnson & Johnson and competitors, covering chemical classes similar to those of US 8,987,333. Major aspects include:
Related patents:
- Prior art: patents filed before 2015 that disclose cholinesterase inhibitors or similar scaffolds.
- Follow-up patents: issued after 2015, citing US 8,987,333 as prior art or building upon its chemical classes.
Key competitors and patent players:
- Eli Lilly and Co.: holds patents on acetylcholinesterase inhibitors, including compounds with comparable scaffolds.
- Pfizer Inc.: owns patents on related neurodegenerative treatments.
- Other biotech firms: filed secondary applications for analogs and formulations.
Patent classifications:
- C07D: Heterocyclic compounds.
- A61K: Medical or veterinary science—preparations for internal or external use.
- A61P: Therapeutic activity of compounds.
Litigation and patent validity:
- US 8,987,333 has remained largely unchallenged until recent adverse action by patent offices in certain jurisdictions.
- Challenges center on the obviousness of chemical structures and the novelty over prior art.
Trends:
- Increasing filings for analogs and formulations post-2015.
- An uptick in international patent applications (WO, EP, CN) citing US 8,987,333 as prior art, indicating expanding global scope.
Patent expiry:
- The patent's expiration date is projected for 2032, assuming standard 20-year patent term from filing in 2011.
Summary table of patent landscape components:
| Aspect |
Details |
| Filing date |
August 23, 2011 |
| Grant date |
March 24, 2015 |
| Patent expiration |
2032 |
| Core chemical scaffold |
Benzazepine derivative with substituted amine groups |
| Claims coverage |
Chemical compounds and therapeutic methods |
| Related patents |
Several filed by competitors post-2015 |
| Jurisdiction |
US, with international filings (WO/EP/CN) |
| Legal status |
Unchallenged, but subject to potential challenge |
Conclusions
US 8,987,333 claims a specific chemical scaffold optimized for activity as a cholinesterase inhibitor, with broad coverage for derivatives and therapeutic use in neurodegenerative diseases. The patent remains relatively strong within the landscape, with ongoing filings expanding the scope worldwide. Competitors focus on similar chemical classes, but Johnson & Johnson’s patent provides robust protection until 2032.
Key Takeaways
- The patent covers a chemical class with potential in Alzheimer’s treatment.
- Claims encompass both compounds and methods of use.
- The patent landscape shows active competition and ongoing filings.
- Legal challenges are limited but may arise due to overlapping chemical claims.
- The patent remains strategically valuable until expiration in 2032.
FAQs
-
Can other companies develop similar compounds without infringing on US 8,987,333?
- Yes, if their compounds do not fall within the specific chemical scope of the claims or do not use the patented methods.
-
How broad are the claims in protecting chemical analogs?
- The claims are broad within the specified chemical scaffold and substitutions, but narrow based on the precise chemical features.
-
What are the key areas of potential patent challenges?
- Obviousness over prior art, novelty over earlier disclosures, or claims exceeding the scope of original inventions.
-
Are there any international patents related to US 8,987,333?
- Yes, filings citing US 8,987,333 exist in WO, EP, and CN jurisdictions, indicating global interest.
-
When does the patent expire, and what are the implications?
- Expiration is projected for 2032, beyond which generic or biosimilar development can proceed freely.
References
[1] U.S. Patent and Trademark Office. Patent US 8,987,333 B2. (2015).
[2] Johnson & Johnson. Patent family filings and legal status reports. (2023).
[3] PatentScope. International patents citing US 8,987,333. (2023).
[4] WIPO. Patent Landscape Reports on neurodegenerative disease therapeutics. (2022).
More… ↓
⤷ Start Trial
|
